KRAS and colorectal carcinoma: Furthermore, the most common driver mutations in CRC cells are BRAF V600E mutation and KRAS mutations [16], and both of these mutations would activate the MAP kinase pathway down-stream of EGFR, and inherently render the affected cells resistant to EGFR-targeted therapy [12,17].